This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/drugbank/drug/DB04049/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04049/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04049/identifier/pdb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB04049/identifier/pubchem-compound/

Statements

Subject Item
n2:DB04049
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n6:DB04049 n11:DB04049
dcterms:title
Coelenteramide
adms:identifier
n9:DB04049 n10:CEI n12:5326781 n13:46506249
n3:synthesisReference
Satoshi Inouye, "Process for producing coelenteramide or an analog thereof." U.S. Patent US20100249387, issued September 30, 2010.
n3:IUPAC-Name
n4:271B5C2F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5C35-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5C34-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5C31-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5C32-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5C33-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5C2D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5C2B-363D-11E5-9242-09173F13E4C5 n4:271B5C2E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5C2C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5C3B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C3C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5C36-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5C37-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5C39-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5C38-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5C3A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5C41-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C43-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C44-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C40-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C3F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C42-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5C30-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5C3D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C3E-363D-11E5-9242-09173F13E4C5